At a glance
ClinicalIndex Comparison Record- ✓Age 18 or older
- ✓Able to provide informed consent
- ✓Histologically confirmed malignancy with metastatic disease on imaging
- ✓At least 11 metastases required
- ✕Serious medical comorbidities precluding radiotherapy
- ✕Moderate or severe liver dysfunction (Child-Pugh B or C) for patients with liver metastases
- ✕Substantial overlap with previously treated radiation volume
- ✕Inability to treat all sites of disease
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Ablative Radiotherapy to Restrain Every Metastasis Safely Treatable (ARREST-2): A Randomized Phase II/III Trial
In Brief
A clinical study evaluating Arm 2: SABR and Arm 1: Standard of Care for Metastatic Cancer. Currently recruiting, targeting 138 participants across 3 sites in 2 countries.
Signals
Detailed Summary
This is a phase II/III international multicentre randomized trial. Patients will be randomized in a 1:2 ratio between the standard of care (Arm 1) and SABR (Arm 2) to all sites of disease. The study will start as a phase II trial with an opportunity to convert to a phase III trial. The objective of this trial is to determine the impact of SABR on overall survival, progression-free survival, quality of life, and toxicity in patients with polymetastatic disease.
Study Details
Timeline
Arms & Interventions
Standard or care palliative radiotherapy (includes the option for no treatment)
SABR to all tumors 6Gy x 5 over 3 weeks
Interventions
SABR to all tumors 6 Gy x 5 over three weeks
Standard of care palliative radiotherapy